Summit Therapeutics Inc. Common Stock (SMMT)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 265
- Market Cap
- $10.7B
About Summit Therapeutics Inc. Common Stock
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
SentiSense also tracks daily options readings for Summit Therapeutics Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Summit Therapeutics Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.